In clinical practice, dose adjustment for SSAs is a common strategy used to manage patients with neuroendocrine tumors (NETs). The primary reason for escalating the dose is to achieve better symptom ...
Merck Announces KEYTRUDA Plus WELIREG Met Primary Endpoint of DFS in Certain Patients With Clear Cell Renal Cell Carcinoma ...
Google AI model helps unmask cancer cells to the immune system: Lead scientist explains breakthrough
Google DeepMind’s AI model generated a ‘novel hypothesis’ about how cancer cells behave, confirmed through lab experiments.
Google AI Breakthrough Highlights Silmitasertib (CX-4945) as a Novel Pathway in Cancer Immunotherapy
Senhwa Biosciences's investigational new drug Silmitasertib (CX-4945) was recently featured in an official post by Google DeepMind, following a major breakthrough by the tech giant's biological ...
Discover Delcath’s innovative liver-targeted chemotherapy system and latest clinical data driving potential market expansion.
Researchers found that pembrolizumab, an immune-activating cancer drug, lowered the risk of distant metastases in patients ...
Sanofi’s $110 million bet on a radioligand seems to be paying off after the neuroendocrine tumor treatment hit the key endpoints of a phase 2 study. The asset in question, dubbed AlphaMedix, is a ...
One of the newest weapons that scientists have developed against cancer is a type of engineered immune cell known as CAR-NK (natural killer) cells. Similar to CAR-T cells, these cells can be ...
In patients with previously untreated diffuse large B-cell lymphoma (DLBCL), polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) demonstrated sustained ...
IMMUNOTHERAPY may offer meaningful benefit for patients with combined small-cell lung cancer, a rare and aggressive tumor subtype that has historically lacked clear treatment strategies. A real-world ...
The Journal of Clinical Oncology podcast, hosted by Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of Clinical Oncology.
What are neuroendocrine tumors (NETs)? Special cells in the body called neuroendocrine cells can act like both nerve cells and hormone-making cells. Neuroendocrine cells are scattered through organs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results